Year in Review: GLP-1 Agonists Dominate Peptide Therapeutics in 2025
As 2025 draws to a close, GLP-1 agonists have cemented their position as the most transformative class in peptide therapeutics, reshaping treatment paradigms across multiple conditions.
The year 2025 has proven to be a watershed moment for GLP-1 receptor agonists, with the peptide class achieving unprecedented clinical, commercial, and regulatory success. From expanded indications to breakthrough pipeline developments, GLP-1 agonists have dominated headlines and reshaped expectations for peptide therapeutics.
What We Know
Market Expansion and Access
The GLP-1 agonist market experienced explosive growth throughout 2025, with combined global sales exceeding expectations set at the beginning of the year [glp1-market-2025]. Semaglutide products (Wegovy, Ozempic, Rybelsus) and tirzepatide (Zepbound, Mounjaro) led the category, with supply constraints finally easing in the second half of the year.
Key market developments included:
- Expanded manufacturing capacity coming online for both major manufacturers
- Increased insurance coverage for obesity indications
- Growing adoption in primary care settings beyond specialist prescribing
- Telehealth platforms significantly expanding patient access
Indication Expansion
Beyond diabetes and obesity, 2025 saw regulatory approvals and compelling clinical data for GLP-1 agonists in additional conditions [fda-approvals-2025]:
Cardiovascular protection: The SELECT trial data led to expanded cardiovascular indications, establishing GLP-1 agonists as cardioprotective agents independent of diabetes status.
Chronic kidney disease: The FLOW trial demonstrated semaglutide’s kidney-protective effects, opening a new therapeutic area for the class.
Metabolic dysfunction-associated steatotic liver disease (MASLD): Multiple GLP-1 and dual agonist candidates showed promise in addressing liver disease, with regulatory submissions anticipated.
Pipeline Advancement
The next generation of GLP-1-based therapeutics advanced significantly in 2025 [obesity-treatment-landscape]:
Retatrutide: Eli Lilly’s triple-agonist (GLP-1/GIP/glucagon) completed phase 3 enrollment, with weight loss results in earlier trials exceeding 24%.
Survodutide: Boehringer Ingelheim’s dual agonist demonstrated efficacy in both obesity and MASH, positioning it for potential 2026 submissions.
Oral formulations: Orforglipron and other non-peptide oral GLP-1 agonists progressed through late-stage development, promising to remove the injection barrier.
CagriSema: The combination of cagrilintide and semaglutide showed enhanced efficacy over semaglutide alone, suggesting combination approaches may define the next wave of treatments.
What It Means
For Patients
The GLP-1 revolution has transformed obesity from a condition with limited pharmaceutical options to one with multiple highly effective treatments. Patients now have choices between injectable and oral formulations, single and dual agonists, and varying dosing regimens. The normalization of pharmacotherapy for obesity has also reduced stigma and increased willingness to seek treatment.
However, challenges remain. Cost and insurance coverage continue to limit access for many patients. Long-term data on weight maintenance after discontinuation remains limited, and the optimal duration of therapy is still being defined.
For Healthcare Systems
The scale of GLP-1 adoption has created both opportunities and challenges for healthcare systems. The potential to reduce obesity-related comorbidities and associated healthcare costs is significant, but the near-term budget impact of widespread adoption has prompted coverage debates in many jurisdictions.
For the Field
GLP-1 agonists have validated the peptide therapeutic modality in ways that benefit the broader field. Investment in peptide drug development has increased, manufacturing capabilities have expanded, and regulatory pathways have become better established. The success has also spurred interest in other peptide-based approaches for metabolic and other conditions.
What’s Next
2026 Outlook
Several key developments are anticipated in the coming year:
- Phase 3 results from the TRIUMPH program for retatrutide
- Potential FDA submissions for survodutide and oral GLP-1 agonists
- Real-world effectiveness data as large patient populations accumulate experience
- Continued indication expansion, potentially including addiction and neurodegenerative conditions
- Generic and biosimilar competition beginning to emerge for older GLP-1 products
Emerging Questions
As the field matures, several questions are gaining attention:
- What is the optimal long-term treatment strategy for obesity?
- How do the various multi-agonist approaches compare head-to-head?
- Can combination therapies achieve outcomes approaching bariatric surgery?
- What role will GLP-1 agonists play in prevention versus treatment?
The year 2025 has established GLP-1 agonists as a cornerstone of modern therapeutics. As 2026 approaches, the field shows no signs of slowing, with the next generation of agents promising even greater efficacy and convenience.
This article is for educational purposes only and does not constitute medical advice. Consult a healthcare provider for personalized medical guidance.
Sources & Citations
- 1
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.